美国Echelon Biosciences www.echelon-inc.com
  Echelon 于1997 年在美国犹他州成立，其前身是美国国家级细胞信号研究中心。Echelon 提供各种抗体、分析检测试剂盒、抑制剂等产品，尤其擅长以细胞信号、脂类代谢和标记物研究为主的相关产品。为研究治疗诸如癌症、糖尿病、炎症、感染和心脑血管疾病专家提供全面有效工具。
  Echelon Biosciences was formed from a project under the Center for Cell Signaling, a State of Utah Center of Excellence, and was incorporated under the laws of the state of Utah as Echelon Research Laboratories, Inc. on October 3, 1997. The company has since changed its name to Echelon Biosciences Incorporated. The company was organized to further the science of lipid cell signaling and critical metabolic enzymes, which provide new and viable targets for the development of potential drugs and diagnostics for cancer, diabetes, inflammation, infections, and cardiovascular disease.
 
  From 1997 through 2004 Echelon primarily used government grants and product sales revenues to fund its research efforts. In early 2005 Echelon was purchased by Aeterna Zentaris (NAS: AEZS) for its MEP antiinfectives, PI 3-Kinase small molecule program and catalog business.
 
  In late 2007, Echelon was acquired by Frontier Scientific Inc. Frontier is based in Logan, Utah; specializing in Porphyrin and related compounds and Photo Dynamic Therapy. The new ownership allows expanded research and funding for many positive aspects for both Echelon and Frontier.